Evestra has established a Scientific Advisory Board (SAB) comprised of distinguished scientists, clinicians and pharmaceutical industry managers with significant expertise in the areas of steroid chemistry, endocrinology, the development of steroidal compounds for use in female health care and oncology and pharmaceutical formulation. All the members are currently actively involved in assisting the company in its product development efforts. This board of advisors is chaired by Evestra’s Executive Vice-President and Chief Scientific Officer, Dr. Klaus Nickisch.
Scientific Advisory Board
Dr. Elger has an international reputation as a thought leader in endocrinology, contraceptives, endometriosis and hormone replacement therapy (HRT). He provided leadership to the Schering AG teams that developed its female health care products such as Jasmine, Angelique, Lilopristone, Onapristone, Cyclodiol, Cyclotriol and Cyproterone acetate. Dr. Elger led all research activities including the collaboration with Takeda-Abbott (TAP) in the development of SPRM/Mesoprogestins and other products. He obtained his M.D. at the University of Munster, where he graduated summa cum laude, and his thesis was in the area of anti-androgens. He was a lecturer at the Free University Berlin, Schering representative to the World Health Organization (WHO) task forces in the area of prostaglandins and anti-progestins and visiting scientist in a number of academic institutions including the University of Texas Medical Branch at Galveston. Dr. Elger received the Schoeller-Junkman award, which is the highest award of the German Endocrine Society.
Walter Elger, M.D.
Former Head Female Health Research, Schering AG and Jenapharm
Dr. Irving M. Spitz graduated M.B., B.Ch. (and his M.D., Ph.D. and D.Sc.) from Witwatersrand University in Johannesburg, South Africa. In 1997 he was elected a Fellow of the Royal College of Physicians of London. Currently he is Director of the Institute of Hormone Research in Jerusalem. Dr. Irving is an Emeritus Professor of Endocrinology at Ben Gurion University, Israel, and Adjunct Professor of Medicine at Weill Medical College of Cornell University, New York. For the past two decades, his research interest has focused on progesterone antagonists and selective progesterone receptor modulators. He conducted some early physiological studies on the mechanism of action of these compounds and directed the first large U.S. multi-center studies with mifepristone. For over 20 years he was a senior scientist at the Population Council in New York, where he was an integral member of a team that developed transdermal, injectable, implantable and vaginal drug delivery systems for steroid and peptides for reproductive health care and cancer. Dr. Spitz is a member of the Endocrine Society, Society for Gynecological Investigation, the European Society of Human Reproduction and Embryology and the American Society for Clinical Investigation.
Irving Spitz, M.D., Ph.D.
Director of the Institute of Hormone Research in Jerusalem, Israel, Emeritus Professor of Endocrinology at Ben Gurion University in Israel, and Adjunct Professor of Medicine at Weill Medical College of Cornell University, New York
Dr. Oettel obtained a Ph.D. in Veterinary Parmacology at Leipzig University in Saxony, Germany in 1964. Co-inventor of the progestin, Dienogest, his background includes more than forty years of work in the field of pharmacological management of reproductive functions in domestic animals and humans at organizations such as University Leipzig G.D.R., Academy of Sciences Jena G.D.R./Germany, Jenapharm, Schering AG/Berlin and the Human Reproduction Program of the WHO in Basle-Switzerland. Honors include the National Award for Science and Technology of the GDR and the Prix Casenne 10th Congress of European Association of Gynecologists and Obstetricians (1995, Monaco). He has co-authored 11 scientific textbooks and is editor of the Handbook of Experimental Pharmacology: Estrogens and Antiestrogens (Springer-Verlag, 1999). He is currently a member of the Governing Board of Naari-AG, a pharmaceutical company based in Basel, Switzerland, the Scientific Board of Gynecura-Förderverein Frauengesundheit in Leipzig and the Leibniz-Sozietät. He is a founding member of the Research Center for Medical Engineering and Biotechnology and the Juratorium Innoven e.V., Jena.
Michael Oettel, Ph.D.
Former Head of Research and Development, Jenapharm
Dr. Raff brings to Evestra his extensive clinical and commercial development experience in the area of female health care. He joined Schering AG in 1977 and was involved in the clinical development of a wide variety of drugs. In 1983 Dr. Raff was promoted to Vice President of Clinical Development and in 1986 to Senior Vice President of Pharma Development at Schering AG. In 1996 Dr. Raff was nominated as the Head of the Strategic Business Unit for Fertility Control and Hormonal Replacement Therapy and was responsible for the commercialization of all of Schering’s pharmaceuticals in the area of female health. He obtained his M.D. in Dusseldorf, Germany, and has been teaching physiology.
Werner Raff, M.D.
Former Head of Female Health SBU, Schering AG
Dr. James W. McGinity is Professor and Division Head of Pharmaceutics at The University of Texas at Austin, College of Pharmacy. His past research interests included physical pharmacy and pharmaceutical technology, and his current research focuses on novel drug delivery systems, including solid dosage forms, microencapsulation, powder technology, transdermal systems and hot-melt extrusion. Dr. McGinity has participated in several national and international scientific symposia and conferences, served as a consultant to the FDA and many national and European pharmaceutical and chemical companies, and has served as U.S. Editor for the European Journal of Pharmaceutics and Biopharmaceutics since 1995. He earned his B.S. in Pharmacy from the University of Queensland, Australia, and his Ph.D. in Physical Pharmacy from the University of Iowa.
James W. McGinity, Ph.D.
Professor & Division Head of Pharmaceutics, College of Pharmacy, The University of Texas at Austin
Dr. Schenken is Professor and Chairman of the Department of Obstetrics and Gynecology at the University of Texas Health Science Center at San Antonio. He obtained a B.S. Degree in Chemistry from Stanford University in 1974 and his M.D. from Baylor College of Medicine in 1977. He completed his residency in obstetrics and gynecology at UTHSCSA and a fellowship in Reproductive Endocrinology at the National Institutes of Health. He is Board-certified in Obstetrics and Gynecology and in Reproductive Endocrinology and Infertility. He is Director for the American Board of Obstetrics and Gynecology (ABOG), and formerly Director of the Division of Reproductive Endocrinology. Dr. Schenken is an examiner for the ABOG Basic and Subspecialty Oral Examinations. He has been a member of the Society for Gynecologic Investigation (SGI) since 1985. He received the SGI President’s Scientific Achievement Award in 1994 and was elected to the SGI Council in 1998. He served as President of the Society for Reproductive Endocrinologists in 1994 and Program Chair for the American Society for Reproductive Medicine (ASRM) in 1996. He served on the Board of Directors for the ASRM from 1997 to 2000 and from 2002 to 2007 and was President of the ASRM in 2005. He serves on several editorial boards and is Associate Editor for the Journal of the Society for Gynecologic Investigation. His clinical and basic research interests are endometriosis, mature women’s health, assisted reproduction and regenerative medicine. He is principal investigator on related research projects funded by the National Institutes of Health and other organizations.
Robert Schenken, M.D.
UTHSC San Antonio (UTHSCSA), Chair, Clinical Gynecology